We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.
- Authors
Waitumbi, John N; Anyona, Samuel B; Hunja, Carol W; Kifude, Carolyne M; Polhemus, Mark E; Walsh, Douglas S; Ockenhouse, Chris F; Heppner, D Gray; Leach, Amanda; Lievens, Marc; Ballou, W Ripley; Cohen, Joe D; Sutherland, Colin J
- Abstract
RTS,S, a candidate vaccine for malaria, is a recombinant protein expressed in yeast containing part of the circumsporozoite protein (CSP) sequence of 3D7 strain of Plasmodium falciparum linked to the hepatitis B surface antigen in a hybrid protein. The RTS,S antigen is formulated with GSK Biologicals' proprietary Adjuvant Systems AS02(A) or AS01(B). A recent trial of the RTS,S/AS02(A) and RTS,S/AS01(B) vaccines evaluated safety, immunogenicity and impact on the development of parasitemia of the two formulations. Parasite isolates from this study were used to determine the molecular impact of RTS,S/AS02(A) and RTS,S/AS01(B) on the multiplicity of infection (MOI) and the csp allelic characteristics of subsequent parasitemias.
- Publication
PloS one, 2009, Vol 4, Issue 11, pe7849
- ISSN
1932-6203
- Publication type
Journal Article
- DOI
10.1371/journal.pone.0007849